Solventum Co. (NYSE:SOLV) Shares Sold by Cohen Capital Management Inc.

Cohen Capital Management Inc. lowered its stake in shares of Solventum Co. (NYSE:SOLV) by 3.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,332 shares of the company’s stock after selling 365 shares during the quarter. Cohen Capital Management Inc.’s holdings in Solventum were worth $790,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. National Bank of Canada FI boosted its position in shares of Solventum by 4.0% during the second quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock worth $314,000 after buying an additional 236 shares during the period. IVC Wealth Advisors LLC boosted its position in Solventum by 5.0% during the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after acquiring an additional 318 shares during the period. Copeland Capital Management LLC bought a new position in shares of Solventum in the third quarter worth $26,000. Mather Group LLC. acquired a new position in shares of Solventum during the third quarter valued at $27,000. Finally, Massmutual Trust Co. FSB ADV raised its stake in shares of Solventum by 64.9% during the third quarter. Massmutual Trust Co. FSB ADV now owns 1,072 shares of the company’s stock valued at $75,000 after purchasing an additional 422 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. BTIG Research assumed coverage on shares of Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating for the company. Stifel Nicolaus began coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. Wolfe Research began coverage on shares of Solventum in a research report on Thursday, September 26th. They issued a “peer perform” rating on the stock. The Goldman Sachs Group raised their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research report on Monday, August 12th. Finally, Piper Sandler began coverage on shares of Solventum in a report on Monday, October 7th. They issued a “neutral” rating and a $71.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Solventum has an average rating of “Hold” and an average price target of $64.33.

Solventum Stock Down 0.2 %

Shares of SOLV opened at $72.46 on Monday. Solventum Co. has a one year low of $47.16 and a one year high of $96.05. The company has a 50-day moving average of $68.90 and a two-hundred day moving average of $61.64. The company has a current ratio of 1.31, a quick ratio of 0.96 and a debt-to-equity ratio of 2.90.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.10. The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.05 billion. Solventum’s quarterly revenue was up .2% on a year-over-year basis. As a group, equities analysts anticipate that Solventum Co. will post 6.38 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.